Good morning, myeloma world.

It's another rainy day here at Myeloma Morning Headquarters, and we're trying to stay positive by keeping in mind that old rhyme, “April showers bring May flowers.”

“Rain is good,” we keep telling ourselves. “Rain is good.”

But we're not so sure, so we're turning our attention to our main task today, which is getting you up to speed on what's new in myeloma world.

In that regard, we'll be focusing first on a brief study …

Good morning, myeloma world.

It's Monday, and the weekend definitely is over. The vigorous activity in our email inbox is making that eminently clear. But, with the week still so young, there isn't much new myeloma research for us to review with you. In fact, we have just two new studies that we'd like to discuss today.

Both studies are by European researchers who have compiled and analyzed retrospective data on some important topics.

One study out of Portugal looks …

Back in February, I wrote about a big decision that I would be facing in a couple of months – whether to go off treatment for the first time since my multiple myeloma diagnosis in June of 2013. It is now two months later, and it is decision time.

I have decided to “take the plunge” into the world of a drug holiday.

“Taking the plunge” may seem like an odd way to phrase it, since this should be …

Good morning, myeloma world.

There are times when we write an edition of Myeloma Morning, and it turns out completely different than expected. Today's edition is a perfect example.

As we were planning today's report, we thought it would focus on two preclinical research studies examining the potential new myeloma therapies CCF642 and BDA-366.

And, yes, we do start today's report with summaries of those two studies.

But readers will be making a mistake if they stop …

Good morning, myeloma world.

We've got a lot of new myeloma-related research to cover today, so we'll get right down to business.

The first two studies we will review are related to autologous (own) stem cell transplantation.

One study looks at whether myeloma cells make their way into the infusion of a patient's own stem cells that a patient gets during the autologous transplant process. The study finds that, in some cases, myeloma cells do make it into the stem …

Seven years have passed since I first ventured to Little Rock, Arkansas, to be treated for multiple myeloma. My youngest daughter was nearly five when I began my journey. When she recently asked me to tell her again about what happened, I put a different spin on the tale:

Once upon a time there was a King who lived with his beloved Queen and their two young Princesses in a tiny castle at the edge of the forest.

They were …

Good morning, myeloma world.

It's just Tuesday, and already the week is getting in­ter­est­ing. We'll be reporting on just two myeloma-related news items today, but one of them is the kind of news we don't see here at Myeloma Morning very often.

In particular, the German bio­tech com­pany MorphoSys has sued Janssen Biotech and Genmab, the two com­pa­nies that have devel­oped and mar­keted Darzalex (dara­tu­mu­mab). MorphoSys contends that sales of Darzalex infringe on a MorphoSys …